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Research
AbstrACt
Objectives To explore general practitioners’ (GPs) routines 
and considerations on (de)prescribing antihypertensive 
medication (AHM) in older patients, their judgement on 
usability of the current guideline and needs for future 
support.
Design Semistructured interviews.
setting Dutch general practice.
Participants Fifteen GPs were purposively sampled based 
on level of experience and practice characteristics until 
saturation was reached.
results GPs appeared reluctant to start AHM, especially 
in patient >80 years. High systolic blood pressure and 
history of cardiovascular disease or diabetes were 
enablers to start or intensify treatment. Reasons to 
refrain from this were frailty and patient preference. 
GPs described a tendency to continue AHM regimens 
unchanged, influenced by daily time constraints, 
automated prescription routines and anticipating 
discomfort when disturbing patients’ delicate balance. 
GPs were only inclined to deprescribe AHM in terminally 
ill patients or after prolonged achievement of target levels 
in combination with side effects or patient preference. 
Deprescription was facilitated when GPs had experience 
with patients showing increased quality of life after 
deprescription and was withheld by anticipated regret 
(ie, GPs’ fear of a stroke after deprescribing). GPs felt 
insufficient guidance from current guidelines, especially on 
deprescription.
Conclusions GPs are reluctant to start or deprescribe 
AHM in older people and have a propensity to continue 
AHM within a daily routine that insufficiently supports 
critical medication review. (De)prescription is influenced 
by patient preferences and anticipated regret and current 
guidelines provide insufficient guidance.
IntrODuCtIOn 
Eighty per cent of older people with hyper-
tension use antihypertensive medication 
(AHM).1 However, treatment recommenda-
tions for people aged 65 and over are limited 
and there is considerable variation in treat-
ment policy between general practitioners 
(GPs).2 3 The European guideline on cardio-
vascular disease (CVD) prevention states that 
in this older population AHM is still effective, 
but that for people over 80 years old target 
systolic blood pressure (SBP) levels may be 
less strict (eg, 140–150 mm Hg instead of 
<140 mm Hg).2 No recommendations are 
provided on deprescription (ie, decreasing 
dosage or discontinuing).
In the past, older people were mostly 
excluded from clinical trials on AHM and 
cardiovascular prevention. More recent studies 
that have included this group have presented 
conflicting results. Overall, antihypertensive 
treatment in the oldest old (>80 years) seems 
to reduce cardiovascular morbidity but has 
no effect on overall mortality.4 The Systolic 
Blood Pressure Intervention Trial (SPRINT) 
provided evidence that intensive BP control 
to a target SBP of below 120 mm Hg could 
prevent CVD and mortality, also in people 
aged ≥75 years.5 6 This trial also showed that 
strengths and limitations of this study
 ► This is the first qualitative study on general prac-
titioners’ (GPs) reasons for prescription and depre-
scription of antihypertensive medication in older 
patients.
 ► A broad diversity in GPs, varying in experience and 
setting, were interviewed because of our purposive 
sampling method.
 ► The interviewed GPs often came to new insights and 
ideas during the interview, when provided with am-
ple time to reflect on decisions that they had made.
 ► Only Dutch GPs were included, potentially limiting 
the generalisability of our results to other general 
practice settings.
 ► Relative few GPs gave examples were antihyperten-
sive medication was started, potentially limiting the 
scope of reasons to start.
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a low target SBP did not result in more orthostatic hypo-
tension, falls or acute kidney injury, which are concerns 
regarding intensive BP treatment.7 However, it remains 
unclear to what extent these results are generalisable.8 9 
On the other end of the spectrum, observational studies 
have shown that in frail people >80 years old a BP below 
140/90 mm Hg might even be harmful as it is associated 
with an increased mortality risk.10 In these oldest old 
people, it may therefore be recommended to restrict 
to two antihypertensive drugs and aim for a maximum 
reduction in SBP of 15 mm Hg.4 10 This, however, is not 
included in the current guidelines.
Our primary aim was to explore GPs’ routines and 
considerations on prescribing and deprescribing AHM in 
older people to clarify the processes underlying current 
(de)prescribing practices. Our secondary aim was to 
assess GPs’ judgement on usability of current guideline 
and their needs for future support in this decision-making 
process to help improve future guidelines on antihyper-
tensive treatment in older people.
MethODs
Participants
Between October 2015 and December 2016, 15 semistruc-
tured interviews were performed. The study was granted 
a waiver from ethical approval by the Medical Ethics 
Committee of the Academic Medical Center (AMC) 
in Amsterdam. All participants gave written informed 
consent. GPs from different geographical areas in the 
Netherlands were invited by telephone or email to partic-
ipate in the interviews. Participants were purposively 
sampled based on years of experience, setting (rural or 
urban) and type of practice (small-scale vs healthcare 
centre), presence of a practice nurse and expertise with 
regard to cardiovascular risk management. Of the 44 GPs 
approached, 15 agreed to participate, 13 could not be 
reached and 16 refused participation. Main reason GPs 
declined to participate was time constraint. After 15 inter-
views, saturation was reached as no important new (sub)
themes emerged over the last interviews.
Data collection
Each interview was done by one of two researchers (TvM 
and SI), both young female physicians trained in qual-
itative interviewing. The interviewers and interviewees 
had no prior relationship and they were aware of each 
other’s profession and level of experience. A prepiloted 
semistructured interview guide (box 1) was developed 
focused on behaviour and attitude in daily clinical prac-
tice to make the interview as concrete as possible and 
limit the influence of socially desirable answers.11 First, 
participating GPs were asked to retrieve recent case histo-
ries on antihypertensive treatment in older patients. They 
were primed for cases in which they recently started, 
increased, continued (without changes), decreased or 
discontinued AHM and were asked to elaborate on their 
routines and considerations in the treatment decision. It 
was left to the discretion of the GPs to decide who they 
considered an older patient. They were allowed to consult 
their electronic health record for further details. Second, 
their views on the value of the current guideline and 
needs for future support were discussed. The interviews 
were held in person at a place that was convenient for the 
interviewed GP (at their practice or home or at the AMC 
or Radboud University Medical Center). The interviews 
took approximately 45 min, were audio-recorded and 
transcribed by the interviewer verbatim.
Data analysis
Transcripts were thematically analysed following an induc-
tive and iterative approach.12 Two researchers (TvM and 
SI) independently coded all transcripts. After every two to 
four interviews, the researchers discussed the codes and 
through comparison and discussion a common coding 
system was developed. The (sub)themes derived from the 
codes were subsequently organised within the prespeci-
fied structure on AHM (de)prescription: starting, inten-
sifying, continuing and deprescribing. At multiple times 
during the data collection and analysis phase, results were 
discussed among a team including a practising GP and an 
expert in qualitative research. Based on these discussions, 
the interview guide was adapted by adding reflective ques-
tions to study the contrast between routine behaviour and 
conscious considerations. Also, the tilting point for (de)
prescription was further specified and the reasons for 
starting AHM were further explored as this is under-rep-
resented at the start.
Patient and public involvement
By exploring GPs’ routines and views, we aim to describe 
daily clinical practice and the support necessary to 
improve clinical practice from a GP’s perspective.
results
Fifteen GPs were interviewed varying in years of expe-
rience from 1 to 30 years (table 1). In daily practice, 
(de)prescription of AHM was consciously evaluated 
when practice nurses noticed a high BP in patients with 
a history of CVD or when patients actively approached 
their GP for their BP, had their BP measured for other 
reasons, for example when moving to an elderly home 
or underwent a critical review on polypharmacy in 
collaboration with the pharmacist. In table 2, the main 
barriers and enablers that GPs mentioned when starting, 
box 1 Main topics in the interview guide
 ► Start or increase antihypertensive medication (AHM): patient from 
daily practice.
 ► Continue AHM: patient from daily practice.
 ► Deprescribe AHM: patient from daily practice.
 ► Current guideline.
 ► Needs and wishes for future guideline support.
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intensifying, continuing and deprescribing AHM are 
presented, illustrated by four cases (table 3). These 
barriers and enablers are further explained in the text 
below.
starting treatment
In general, GPs were somewhat reluctant to start AHM in 
older patients. This was especially true for the oldest old 
patients (>80 years), for patients with a limited life expec-
tancy (<1–2 year) and for frail patients. In these cases, GPs 
only started AHM when SBP was higher than 180 mm Hg. 
GPs evaluated frailty based on their clinical impression 
and physical, cognitive and overall functioning. One GP 
was cautious because of the psychological impact starting 
medication could have on patients:
Sometimes I think that the added value (of starting 
AHM) in patients at older ages is minimal, but it does 
have a huge impact if I say, ‘Well you have a high BP 
and you need medication for it’. I think in some cases 
I am inclined to say to myself, ‘Well then just leave it’ 
[don’t start AHM]. (GP 3, male, 5–10 years’ experi-
ence as GP)
GPs felt more inclined to start AHM in patients with 
a history of CVD (ie, secondary prevention) or diabetes 
and in case of a planned operation. GPs were reluctant 
to start AHM when patients felt resistant towards medica-
tion or, on the contrary, were inclined to start AHM when 
patients were fearful for the consequences of a high BP:
I have an older female who was very afraid for her 
high BP. She used to have an angiotensin-converting 
Table 1 Participant characteristics
Characteristic Population (n=15)
Sex 
  Male 8 (53%)
Age 
  <40 years 7 (47%)
  40–50 years 3 (20%)
  >50 years 5 (33%)
Years as a GP 
  0–5 years 4 (27%)
  5–10 years 3 (20%)
  10–15 years 3 (20%)
  >15 years 5 (33%)
Academically affiliated*7 (47%)
Location 
  Urban 8 (53%)
  Rural 7 (47%)
Practice type 
  Solo 2 (13%)
  Duo 4 (27%)
  Group 8 (53%)
  Other† 1 (7%)
Practice nurse available 10 (67%)
Characteristics of the participating general practitioners.
*Academically affiliated indicates either working at an academic 
centre for educational or research purpose or working as GP 
trainer.
†One GP worked as locum GP in different practices.
GP, general practitioner.
Table 2 Main barriers and enablers to start, intensify, 
continue or deprescribe antihypertensive medication
Enabler Barrier
Starting AHM 
  High SBP (> 180  mm Hg) Age > 80  years 
  History of CVD/DM Limited life expectancy 
  
  Planned operation 
Frailty
  Patient preference Psychological impact of 
starting medication 
Patient preference 
Intensifying AHM 
  High SBP (>140 or 
>160  mm Hg) 
Age> 80  years 
  Age <80 years ≥3 antihypertensive drugs 
  History of CVD/DM Patient preference 
Frailty
Continuing AHM 
  Automated prescription 
routines
  Time constraints 
  Requires less justification 
than deprescribing/
intensifying 
  Anticipating discomfort 
when disturbing the 
precarious balance 
  Target BP level not yet 
reached 
Deprescribing AHM 
  Prolonged achievement of 
target BP 
Anticipated regret 
  Side effects, orthostatic 
hypotension 
Deprescribing may give the 
impression of giving up on a 
patient 
  Risk of falling AHM gives patients a sense 
of control 
  Patient preference 
  Experience with increase in 
quality of life 
  Terminal illness 
AHM, antihypertensive medication; BP, blood pressure; CVD, 
cardiovascular disease; DM, diabetes mellitus; SBP, systolic blood 
pressure.
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enzyme (ACE) inhibitor which I stopped, or reduced. 
I strictly monitored her BP for 6 months; during 
which it was always good. And then, a few months 
later, it went up again; systolic (BP) around 190 or 
200. And then she became very anxious. So she want-
ed her ACE-inhibitor back. (GP 1, male,>15 years’ 
experience)
Intensifying treatment
Intensifying treatment in patients already receiving 
AHM (ie, increasing dosage and/or supplementing by 
adding another antihypertensive drug) seemed relatively 
straightforward. This was proposed for a SBP higher than 
140 mm Hg in patients younger than 80 years or with a 
history of CVD or diabetes and for SBP readings higher 
than 160 mm Hg in patients older than 80 years. GPs 
experienced more uncertainty when patients already used 
at least three antihypertensive drugs or when patients 
wished to refrain from intensifying treatment:
I often see that people do not want this much med-
ication. That they just want to feel comfortable at 
home. Then (at older ages) you will look more at 
the person behind the illness. (GP 5, male, >15 years’ 
experience)
Another reason not intensify treatment was frailty:
(Interviewer: How does frailty influence your choice 
with regard to AHM?) That your target BP is less 
strict. That you will accept a BP of 165 over 95 and 
not give someone extra medication. While in the fit 
older patient you will think, let’s give it a go (increase 
AHM). (GP 2, female, 10–15 years’ experience)
Continuation of treatment
Continuation of AHM with unchanged regimens was 
often not an active choice but a consequence of auto-
mated repeat prescription algorithms in the electronic 
health record. In combination with time constraints 
within the general practice organisation, this prompted 
swift, global checks of AHM regimens only without room 
for an assessment whether the prescribed medication was 
still appropriate. In some cases, GPs thought it might have 
been better if they deprescribed AHM; however, they felt 
that leaving the drug regimen unaltered would require 
less justification than changing things around:
I also think that it is easier to simply continue a treat-
ment. I feel that changing a treatment requires much 
more justification and should also be done in consul-
tation with the patient or family. Sometimes it can be 
easier to just consent to a repeat prescription, than 
to repeatedly consider whether it is still appropriate. 
(GP 8, male, 0–15 years’ experience)
When continuation of AHM was an active choice, an 
important motivation for leaving things as they were was 
the perception that some patients had found a precarious 
balance and changing AHM (ie, increasing or decreasing) 
could increase the risk of discomfort:
Table 3 Quotes about patient cases to illustrate antihypertensive medication (de)prescription
  Start AHM “We had a woman who just moved into an elderly home and came under our care. This is a woman of 
91 years old. She came to live there with her husband, because of her age and because she had mild 
dementia. And when she arrived at the home for elderly they immediately measured her BP. She had a 
BP of 190 over 90. And so we gave her losartan 50 mg. […] So before that she had no AHM. Well you 
may think, that doesn’t do much, it isn’t that much. And so, we gave it. Then her BP immediately went 
to 140 over 80 and it remained there. And then she started complaining about terrible dizziness. And 
so I stopped it again.” (GP 12, female, >15 years’ experience as GP)
  Intensify AHM “This is also a very fit lady, but she is 86 years old. She had hydrochlorothiazide 12.5 mg and we 
increased that to 25 mg, because she had a BP of 180 over 80. And now with 25 mg it is 160 over 80. 
And she feels fine, so we leave it like this.” (GP 6, female, 10–15 years’ experience)
  Continue AHM “A patient of 92 years old, I think. Known with heart failure, poor mobility and COPD. She wants as 
little as possible. Also she doesn’t want to go to the hospital. And her BP is actually not much of an 
issue. Even though we know it is higher from time to time. When the oedema increases, her legs are 
swollen and she gets shortness of breath on exertion, well then we always measure the BP to see 
how much room we have to increase the furosemide. And there is always enough room, she always 
has a BP of 170–180. So that is nice, that we have that. But it never crossed my mind, when we have 
treated the fluid retention, to follow-up on her BP to say, let’s see if we should treat this structurally.” 
(GP 15, female, 10–15 years’ experience)
  Deprescribe AHM “Here I have the file of a 69 years old woman who has stage four lung cancer with progressive brain 
metastases. […] Because of a language barrier, her daughter explained that her mother often felt 
dizzy when getting up. She first called it vertigo, but after some further questioning it appeared more 
like light headedness. […] Her BP was repeatedly around 124 over 70. And what I did was, first I 
stopped the hydrochlorothiazide. Then her BP stayed low and she was still dizzy. And in the end I also 
stopped her losartan. […] And now her BP stays around 130 over 80, but now without any AHM. So in 
hindsight I think she was severely over-treated.” (GP 11, male, 0–5 years’ experience)
AHM, antihypertensive medication; BP, blood pressure; COPD, chronic obstructive pulmonary disease; GP, general practitioner.
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And reducing, well I think that… it’s like ‘never 
change a winning team’. If someone is doing well 
and has no complaints, then you are not inclined 
to…(change AHM). (GP12, female, >15 years’ 
experience)
Finally, one GP thought that aiming for a certain BP 
target also contributed to the steady state in repeat AHM 
prescriptions, which kept her from regularly re-evaluating 
whether they were still appropriate:
I think that, if I look at my experience, when you have 
made the decision to act on a BP, I think that you 
are more inclined to continue your aim for the target 
BP that you have set. […] I think that you tend to 
just proceed and not use every evaluation moment 
to reconsider whether you should continue with it 
(treatment). Which really would have been very ap-
propriate. But I notice that I do not do that myself. 
(GP 15, female, 5–10 years’ experience)
Deprescribing treatment
Reducing or discontinuing AHM was not something that 
was easily decided on. It required clear motives apart 
from a prolonged period during which the BP was at or 
below target level, including side effects of AHM, ortho-
static hypotension, a high risk of falling and patient pref-
erence. Some GPs had experience with an increase in 
quality of life (for example feeling less tired) of patients 
after deprescribing AHM:
When I stop AHM in older patients they often feel 
much better. Then the BP rises somewhat and they 
feel less tired. Well I don’t know if it is caused by that, 
but sometimes I think that. (GP 1, male, >15 years’ 
experience)
In some cases, the decision of GPs was influenced by 
anticipated regret: the fear that a patient might have a 
stroke after deprescribing AHM:
And it requires a sort of courage to notice that when 
you reduce AHM, the values, the indicators, increase. 
And you have to feel comfortable with that. If you 
withdraw AHM and someone, say after six months, 
has a stroke, than you suddenly feel uncomfortable. 
(GP 5, male, >15 years’ experience)
GPs acknowledged that in the terminal phase it would 
be rational to discontinue AHM. However, they often 
hesitated to take this step to avoid the impression they 
were giving up on the patient or unnecessarily deprive 
them of a sense of being in control with adequate BP 
measurements. They aimed to avert the risk of non-fatal 
stroke and the accompanying functional limitations in 
the last phase of life.
Current guideline and future support
During the interview, when provided with ample time to 
reflect on decisions that had been made, the interviewed 
GPs came to new insights and ideas. They stated that in 
daily practice treatment decisions were often based on 
intuition and that it might have been better if they had 
deprescribed AHM earlier:
I often do this briefly in between my consultations. 
And I notice, now that we are talking about it… it 
forces you to critically think about it. And then I 
think, oh I could do this better. And of course we can 
always do our work better; nobody knows everything. 
But I do think that, now that you mention this and we 
critically look at it, I should think this through more 
thoroughly. (GP 11, male, 0–5 years’ experience)
GPs generally felt insufficiently supported by the guide-
lines in their efforts to treat hypertension in older people:
Yes, whom to treat and whom not to treat among the 
oldest old. […] The healthy you have to treat, be-
cause they still have a long life expectancy and there-
fore have much to gain in lowering their BP. Those 
with diseases, like the patients with diabetes or a myo-
cardial infarction, you have to treat because they have 
a substantially elevated risk because of their disease 
that we are well able to bring down. That group in 
between, with frail elderly, I followed the advice not 
to treat them for a while. And now I recently heard 
that you also have to treat those. I just don’t know it 
anymore. I would really like to have a guideline that 
states: in elderly you have pay attention to this, this 
and this. (GP 9, female, 5–10 years’ experience)
A GP suggested a treatment flow diagram including 
more subjective factors like frailty for future support or 
indicators to start or deprescribe AHM like the Screening 
Tool of Older Person’s Prescriptions (STOPP)/Screening 
Tool to Alert doctors to Right Treatment criteria.13 
Another suggestion was to aid deprescription by incorpo-
rating algorithms in the electronic health record that aid 
doctors and practice nurses in observing complaints that 
are potentially related to a low BP.
DIsCussIOn
For Dutch GPs, starting or intensifying antihypertensive 
medication is guided by the absolute level of SBP, history 
of CVD and diabetes. GPs feel reluctant to start AHM at 
older age, but when someone already receives AHM they 
also feel reticent in accepting a high BP (ie, not intensifying 
AHM). They may refrain from intensifying AHM in cases 
of frailty or clear patient preference. There is a propensity 
to continue AHM in older people within a daily routine 
that insufficiently supports critical review of prescrip-
tions due to time constraints and automated prescription 
routines. Continuation of AHM is also supported by antic-
ipating discomfort when disturbing patients’ delicate 
balance and the perception that continuing treatment 
requires less justification. The decision to deprescribe 
AHM is difficult, although GPs also mention a possible 
gain in quality of life, such as less fatigue. Deprescription 
is only considered when BP is consistently at or below the 
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target, and a patient experiences side effects or wants to 
reduce treatment. Anticipated regret of a future stroke 
may represent an additional barrier for deprescription. 
GPs experience insufficient guidance on antihypertensive 
treatment for older people and would welcome a treat-
ment flow diagram including specific STOPP criteria as 
well as more subjective factors like frailty.
An important strength of our study is the diversity of GPs 
that were interviewed, with a broad range in experience 
and setting. The interview guide was aimed at discussing 
examples from daily clinical practice to limit the chance 
of socially desirable answers. We followed the consoli-
dated criteria for reporting qualitative research guide-
lines to improve the interpretation and reproducibility of 
our results.14 A limitation is that our study only includes 
Dutch GPs, which may restrict the level of generalisability. 
The role of Dutch practice nurses within the cardiovas-
cular prevention programmes has become more prom-
inent over the last years (box 2).15 This probably limits 
the time Dutch GPs spend on antihypertensive treatment 
and may facilitate routine continuation of AHM. Since 
specific directives on BP treatment for older people are 
lacking in most international guidelines, the feeling of 
limited support is likely found in other countries as well. 
Relative few patient cases were discussed were AHM was 
started due to the reluctance of GPs to start AHM in older 
patients and the notion that a lot of the older patients 
already received AHM. Even though data saturation was 
reached, this could have potentially limited the scope of 
reasons to start AHM.
No other qualitative study has assessed GPs’ reasons 
for prescription and deprescription of antihypertensive 
medication in older patients. There are however previ-
ously reported studies with a broader focus on cardio-
vascular prevention, which have shown results consistent 
to ours.16–18 These studies stated that GPs are uncer-
tain about many aspects of cardiovascular prevention, 
including the application of guidelines, organisation of 
care and benefit for individual patients and that they are 
less likely to prescribe preventive medication in frail older 
people.3 16 17 Especially when focusing on AHM, the uncer-
tainties are most likely fuelled by the conflicting available 
evidence. There is both evidence in favour of intensifying 
treatment as well as studies that support a higher target 
BP.6 10 These uncertainties may lead to overtreatment by 
unnecessary continuation of AHM regimens, or to under-
treatment, caused by the reluctance to initiate treatment 
in older people who are still free from AHM. As contin-
uation also seems to be a consequence of daily routine 
influenced by time constraints and automated prescrip-
tion routines, overtreatment might be prevented by more 
structural time for medication reviews. Patient prefer-
ence plays a crucial part in (de)prescribing and should 
be actively taken into consideration, for example through 
use of the outcome prioritisation tool.19 In addition, an 
estimation of frailty seems important which, by its subjec-
tive nature, could bring about the large variation in treat-
ment intentions of GPs, which was previously described in 
a Belgian vignette study.20
The reluctance to deprescribe AHM in older patient 
is also noted for other drug classes.21 This reluctance is, 
among other factors, induced by GPs’ anticipated regret, 
which has been previously described as a motivator to start 
or continue preventive treatment.17 22 The fear of ‘causing’ 
a stroke by deprescribing AHM is unsupported by clinical 
evidence but might be instigated by results from trials 
like the SPRINT trial that support intensive BP lowering,6 
even though multimorbid older people are potentially 
under-represented in this trial and the generalisability of 
these results is uncertain.8 Also for deprescribing shared 
decision-making is crucial.21 Older patients have varied 
attitudes and ideas about their medication use and clear 
communication is therefore crucial.23 However, given the 
present knowledge gaps, risk communication is perceived 
difficult by GPs.24 Until now, deprescribing AHM is only 
supported by observational studies, which have demon-
strated an association between a low or decreasing BP 
and worse functional outcome, cognitive decline and 
increased mortality.25 26 The Discontinuation of Antihy-
pertensive Treatment in Elderly People trial showed that 
discontinuation of AHM was safe, although not beneficial 
on cognitive, psychological or general daily functioning 
during the relatively short 16-week follow-up.27 To make a 
better informed decision on the deprescription of AHM, 
it would be useful to have additional evidence on the effi-
cacy of deprescription with longer follow-up and on the 
subjective and objective impact of AHM in older people. 
For GPs, it would be desirable to add indicators for depre-
scription (ie, STOPP criteria) in the guideline as this is 
what GPs consider difficult.
Dutch GPs are reluctant to start or deprescribe AHM 
in older people. Continuation of AHM is reinforced by a 
daily routine that insufficiently supports critical medica-
tion review and conflicting available evidence on efficacy 
of intensifying treatment. Patient preference appears 
box 2 Antihypertensive treatment in Dutch general 
practices
 ► Almost all Dutch citizens are registered at a general practice.
 ► In the Netherlands, general practitioners (GPs) have a gatekeeping 
role and are relatively easy accessible.28
 ► Approximately 75%–80% of medication is therefore prescribed by 
GPs.29
 ► In 2006, the guideline on hypertensive treatment was combined 
into a more general guideline on cardiovascular risk management 
(CVRM).30
 ► Recommendations in this guideline are similar to the European 
guideline, aside from the Systematic Coronary Risk Estimation chart 
which is expanded up to 70 years and the target systolic blood pres-
sure for people over 80 years old which is 150–160 mm Hg.2
 ► With the introduction of nurse-led CVRM, over the last decade, the 
workload for GPs decreased and guideline adherence improved.31
 ► Specialists are mainly responsible for starting antihypertensive 
treatment in patients with secondary prevention, while general 
practitioners play a crucial part in primary prevention.
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crucial for both prescribing and deprescribing. Antic-
ipated regret of a future stroke works as a barrier for 
deprescription. Current guidelines provide insufficient 
guidance and clear indicators on deprescription could 
endorse it.
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